News

Diabetes scientists, doctors, investors gather at Hui Lecture Hall to talk about new drug development and clinical challenges

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2021-06-18
  • Views:0

(Summary description)Recently, scientists, clinicians and financial investors in the field of glucose metabolism diseases gathered at the WSP Huilu College of Pharmacy Huilu Lecture Hall to share and discuss with professors of WSP Huilu College of Pharmacy on the theme of "R&D strategy and layout of next-generation drugs for glucose metabolism and its derivative diseases", in terms of drug development direction and R&D and clinical challenges.

Diabetes scientists, doctors, investors gather at Hui Lecture Hall to talk about new drug development and clinical challenges

(Summary description)Recently, scientists, clinicians and financial investors in the field of glucose metabolism diseases gathered at the WSP Huilu College of Pharmacy Huilu Lecture Hall to share and discuss with professors of WSP Huilu College of Pharmacy on the theme of "R&D strategy and layout of next-generation drugs for glucose metabolism and its derivative diseases", in terms of drug development direction and R&D and clinical challenges.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2021-06-18
  • Views:0

 

Recently, scientists, clinicians and financial investors in the field of glucose metabolism diseases gathered at the WSP Huilu College of Pharmacy Huilu Lecture Hall to share and discuss with professors of WSP Huilu College of Pharmacy on the theme of "R&D strategy and layout of next-generation drugs for glucose metabolism and its derivative diseases", in terms of drug development direction and R&D and clinical challenges.

 

Dr. Tong Wang, Chief Scientist of CGeneTech (Suzhou, China) Co., Ltd. opened this session of Wise Lecture Hall with a lecture on "New Drug Development for Glucose Metabolism and Derived Diseases".

Dr. Tong Wang analyzed and summarized the current situation of diabetes market from the aspects of pathogenesis, etiology, typological changes, complications, patient distribution and basic market situation, as well as the epidemic characteristics of diabetes in China, introduced the conditions of glucose metabolism derived diseases such as obesity, cardiovascular disease, nephropathy, non-alcoholic steatohepatitis and foot ulcer, and shared the glucose metabolism and its derived diseases with the representative varieties of CGeneTech and the market as examples. and its derivative diseases, and shared the frontier progress of new drug development.

In the roundtable session, chaired by Prof. Lei Fu (below), Vice President of the Westwood College of Pharmacy, a number of industry guests discussed the future drug development directions, clinical challenges and strategies for next-generation glucose metabolism and its derivative diseases.

 

 

Dr. Shao Xinyu, Director of the Department of Endocrinology, Dushu Lake Hospital, Soochow University (pictured below), shared the latest clinical situation of diabetes and its derivative diseases, current patient growth, individual differences, treatment difficulties, and the latest cutting-edge treatment tools and directions.

 

Regarding the need for innovative drugs, he said that from the perspective of clinical treatment, many of the existing drugs for diabetes only focus on lowering blood sugar, while doctors are looking for more than just a simple glucose-lowering drug, and it would be a better drug if it could help with cardiovascular, cerebrovascular, kidney protection, or weight loss.

Dr. Wang Tong responded that despite the large diabetic population, China's current drugs for diabetes "seem a bit outdated.

According to the 2018 Top 10 Generic Names of Diabetes Drugs in China's public healthcare institutions, acarbose topped the list, insulin took four seats, and metformin ranked first in growth.

These old drugs, Dr. Wang said, are taken with certain restrictions and accompanied by certain side effects. "For example, acarbose, the best time to take it must be before meals, in addition to the gastrointestinal side effects; glimepiride, will produce the side effect of hypoglycemia." For some people, some side effects can be fatal," he said. But those drugs that are relatively a bit outdated, the growth rate of drug use in China is still quite high, so we must have a renewal."

He further said that in the direction of drug innovation can not be lowering sugar as the only goal. "High blood sugar can cause damage to blood vessels with nerves, so diabetes often causes a variety of complications and derivative diseases, such as eye disease, kidney failure, cardiovascular disease, foot lesions, obesity, non-alcoholic steatohepatitis, etc. The high incidence of complications and eye diseases make it impossible to make sugar reduction the only goal of the new generation of diabetes treatment when developing diabetes drugs; we have to consider derivative diseases and complications."

Dr. Shunfei Yan (pictured below), Investment Manager at Fosun-Star Future Capital, shared the challenges facing new drug development from an investor's perspective. He noted that the development of innovative drugs is likely to be constrained by future market price factors. He cited the example that many patients are more sensitive to drug prices, and even if an innovative drug with better efficacy comes out, many patients are reluctant to pay the extra price and would rather wait for the drug's patent to expire and the price to drop before using the drug.
 

In terms of investing in the layout of diabetes drugs, Dr. Yan said that according to the market research, their focus is not only on simply lowering sugar itself, but more on whether the new drug has synergistic therapeutic effects on glucose metabolism-derived diseases, such as fat reduction for the prevention and control of glucose metabolism diseases.

Professor Wang Mu (pictured below), executive dean of the Westwood College of Pharmacy, said that drug development for diabetes has been a cutting-edge topic in the biomedical field. "Because diabetes is not curable yet, most drugs can only control blood sugar." He said, "So we need to use innovative thinking to make innovative drugs. The old methods don't seem to work, and you have to think outside the box to come up with new strategies that are not guaranteed to be successful, but at least will have a better chance."

Dr. Qiang Yu (pictured below), President and CEO of CGeneTech (Suzhou, China) Co., Ltd. believes that the Wise Lecture was particularly well run. "There is both source innovation (SIP), industrial translation (CenteneTec), clinical research (Dushu Lake Hospital) and capital injection (Star Future)." He said, "So we all work together to be able to make this emerging industry in the domestic biopharmaceutical industry in the field of big health bigger and better."

At the end of the event, Prof. Lei Fu expressed his gratitude to the guests: "Thank you to all the guests present today and all the colleagues who are in the front line of drug development, clinical application and capital layout together with them, for their long-term and unremitting efforts in innovative R&D, clinical application and capital investment in glucose metabolic diseases, and for their persistence in guarding our lives with their lives! !"

This edition of the Wise Lecture was co-organized by the WPI Huizhou College of Pharmacy, Centurion Biomedical Technology (Suzhou) Co., Dushu Lake Hospital affiliated to Soochow University, Fosun-Stellar Future Research Institute, Suzhou Biomedical Industrial Park, and Suzhou Intellectual Property Operation Association, and was also simulcast live online on WPI's WeChat public video number.

About Xi Pu Huihu College of Pharmacy

 

It aims to collaborate with the government, industry and society to incubate a world-class biopharmaceutical international innovation ecology and help Suzhou's "No. 1 industry" to build a world-class biopharmaceutical industry landmark. As a research and practice oriented college, the college responds to the needs of enterprises, integrates into enterprises, shares educational contents, processes and resources, builds a deep collaboration mechanism with enterprises, and actively cultivates international applied, high-end composite, scarce and ready-to-use talents that enterprises need and apply.

About WiseTalk

The Wise Lecture is a monthly brand event organized by the Westwood College of Pharmacy, which will be divided into two sections: the Frontiers of Medicine Series and the Science Communication Series, dedicated to sharing the academic frontiers and industry developments in the biomedical field for the scientific research community and the biomedical industry, and introducing and disseminating scientific knowledge on biomedicine and health and nutrition to the public.

The

The world's first SGLT-2/DPP-4 dual target inhibitor with complementary advantages has been approved for clinical use

Recently, Shengshi Taike's Class 1 innovative drug SGLT-2/DPP-4 dual target inhibitor CGT-2201 has been granted implicit permission for clinical trials by the National Drug Administration. CGT-2201, which targets SGLT-2 and DPP-4, two important targets related to glucose metabolism, can be better used for the treatment of diabetes and its derivatives, including diabetes nephropathy and non-alcoholic fatty liver disease. In 2021, the number of diabetes patients in China will reach 141 million, ranking first in the world. Among the numerous patients with diabetes in China, 20-40% may suffer from complications of diabetes nephropathy. Among the existing hypoglycemic drugs, only sodium glucose cotransporter 2 (SGLT-2) inhibitor has significant renal protection effect in clinical verification, but its inherent reproductive and urinary system infection risks limit its use. Based on SGLT-2 inhibitors and combined with the characteristics of dipeptidyl peptidase 4 (DPP-4) inhibitors, we design and develop a drug that can improve blood sugar, reduce side effects of urinary and reproductive system infections, is not limited by renal function, and has kidney benefits. It is expected to fill the market gap and meet the needs of patients. Based on this market background and target characteristics, Shengshi Taike utilizes its own small molecule chimera drug technology platform to develop multi head multifunctional new drug products with synergistic mechanisms, with CGT-2201 being one of its representative works. It fuses the respective mechanism characteristics of SGLT-2 and DPP-4. On the basis of inhibiting the activity of SGLT-2 to reduce the reabsorption of glucose in the kidney, it also slows down the inactivation of DPP-4 on GLP-1, playing a dual role mechanism to play a superposition effect; While achieving considerable hypoglycemic effect, it can reduce the side effects of existing SGLT-2 drug urinary system infection; At the same time, without kidney excretion, it can reduce the burden of the kidney and reduce the contraindication of diabetes patients with renal insufficiency. Therefore, this drug will have the advantage of better controlling blood sugar and protecting patient kidney function. Shengshi Tyco was founded in Suzhou Industrial Park in 2010. Its core team has decades of experience in the whole life cycle of international drugs, and is committed to the R&D and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a product pipeline covering multiple disease fields such as hypoglycemic, anticancer, and autoimmune diseases with an integrated drug research and development technology platform and a diversified business perspective. In the field of hypoglycemic drugs, Shenggliptin, the core product independently developed by the company, has submitted an NDA (product launch application) to the National Drug Administration and has been accepted. The results of the Phase 3 clinical trial showed that low doses can reach the predetermined trial endpoint, while the high-dose group can also demonstrate the safety of the drug well. The therapeutic effect of "half the dose" is twice as effective, making it expected to become the best hypoglycemic drug in the class. At the same time, the company has also carried out a comprehensive layout around oral drugs and derivative diseases of various targets related to diabetes. CGT-2201, which was approved for clinical use this time, is one of its pipeline matrix members.
2023-04-20

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO